• Monday, 21 June 2021
booked.net
*Dollar holds near multi-month high after Fed's hawkish tilt  *Indonesia reports 83 missing fishermen in six months  *Two Cambodian Swimmers To Attend Tokyo Summer Olympics 2021  *Malaysia on track to achieve herd immunity  *Johnson Plans U.K. Science Superpower With $21 Billion R&D Spend  *JICA intensifies collaboration with Vietnam in several fields in FY2021  *Father-son movie excels on Father's Day in China  *India auto hub lets car plants run at full capacity despite few vaccinations  *Support rising in Japan for Tokyo Olympics this summer  *American Airlines to cut 1% of July flights as travel rebound strains operations 

Third member of US FDA advisory panel resigns over Alzheimer's drug approval

Third member of US FDA advisory panel resigns over Alzheimer's drug approval

WASHINGTON - A third member of a panel of outside advisers to the US Food and Drug Administration has resigned in protest over the agency's decision to approve Biogen's Alzheimer's disease treatment despite the committee's recommendation against doing so.

 

Aaron Kesselheim, a Professor of Medicine at Harvard Medical School who had served on the FDA’s advisory committee for nervous system drugs since 2015, told Reuters on Thursday he was stepping down from the panel.

 

"My rationale was that the FDA needs to re-evaluate how it solicits and uses the advisory committees ... because I didn’t think that the firm recommendations from the committee in this case ... were appropriately integrated into the decision-making process," Kesselheim said in an email. He cited FDA's decision to approve Sarepta Therapeutic Inc's drug, eteplirsen, for Duchenne muscular dystrophy in 2016 as another example of the regulator approving a drug against the recommendations of its advisory committee.

 

Stat News first reported his departure

On Tuesday, a member of the advisory group who voted against the approval, Washington University neurologist Dr. Joel Perlmutter, resigned from the committee, citing the FDA's approval of Aduhelm. Mayo Clinic neurologist Dr David Knopman said he resigned on Wednesday.

 

The 11-member committee voted nearly unanimously in November that Biogen's drug should not be approved, citing inconclusive evidence that the drug was effective. The FDA on Monday gave the drug "accelerated approval,” based on evidence that it can reduce a likely contributor to Alzheimer’s, rather than proof of a clear benefit against the disease.

 

Source: CNA

Comment / Reply From